Showing results (221-230 of 258) with videos related to
Sort By:
Pageof 26
BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.Japanese Journal of Clinical Oncology|November 18, 2022
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trialHiroji Iwata, Rikiya Nakamura, Norikazu Masuda, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.Oncotarget|March 15, 2018
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancersCarole Sourbier, Pei-Jyun Liao, Christopher J Ricketts, et al.Cancer Research|May 17, 2018
Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate CancerMichael A Moses, Yeong Sang Kim, Genesis M Rivera-Marquez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerYang-Min Ning, James L Gulley, Philip M Arlen, et al.Cancer Cell|December 10, 2014
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancerCarole Sourbier, Christopher J Ricketts, Shingo Matsumoto, et al.Blood|June 24, 2005
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutationJason Gotlib, Caroline Berubé, Joseph D Growney, et al.Pageof 26